Whitehawk Therapeutics

Whitehawk Therapeutics

Biotechnology
Whitehawk Therapeutics Inc is a preclinical stage oncology therapeutics. The company is engaged in applying technologies to established tumor biology to efficiently deliver improved cancer treatments. The company's three-asset ADC portfolio is engineered to overcome the limitations of first-generation predecessors to deliver a meaningful impact for patients with difficult-to-treat cancers.

$177.6M

Market Cap • 11/16/2026

2007

(19 years)

Founded

2021

(5 years ago)

IPO

NASDAQ

Listing Exchange

Flag of United States

United States

Country

Valuation

P/B

1,1

P/S

—

P/EBITDA

—

P/OCF

—

P/FCF

—

P/E

—

BVPS

2,8

EPS

—

Market Cap

Market Cap

177,6M

EV

8,2M

EV/Revenue

—

EV/EBITDA

-0,1

EV/EBIT

-0,1

Payout

Dividend Per Share

0

Dividend Yield

0%

Buyback Yield

-49,3%

Total Yield

-49,3%

Dividend Yield 5Y

0%

Payout

0%

Retained Earnings

-413,3M

Profitability

Gross Margin

—

EBITDA Margin

—

EBIT Margin

—

Net Margin

—

D&A/EBITDA

0%

R&D/Revenue

0%

Capex/Revenue

0%

Capex/D&A

100%

Capex/OCF

0%

SBC/OCF

—

% PPE

0,1%

% Goodwill

0%

ROE

—

ROIC

—

Growth

CAGR Revenue 5Y

-100%

CAGR Net Income 5Y

-0,7%

CAGR EPS 5Y

-34,2%

Leverage

N.D./EBITDA

1,9

Debt/Equity

0%

Current Ratio

16,5

Quick Ratio

16,3

Interest Coverage

—

Premium

Unlock 100% of the data and have immediate access on more than 6.000 companies with updated information!
  • Unrestricted access
  • Unlimited data history
  • Analysis videos
  • Quarterly highlights
  • Customizable financials table
  • Ranking
  • Discussions

...and much more!

Get Premium